Life sciences company Adaptive Biotechnologies Corp. has bet on using the immune system to treat and diagnose diseases, and they have made good on that bet. The company has been issued 25 patents, has created a database of immune system information sold to over 125 companies and 200 researchers, and has substantial partnerships with both Microsoft and Genentech. Part of the success of the 10-year old company comes from the rise of machine learning, as its most recent patent filings demonstrate. Now, in the midst of huge growth, the company is planning to go public in a hopes to raise $230 million. These funds will support getting FDA authorization for the use of its sequencing services for lymphoma, approval of a clinical indication, and getting a cell therapy through the IND submission process.
